The rapid rise of Glucagon-Like Peptide-1 (GLP-1) therapies is reshaping diabetes and obesity management worldwide. As semaglutide patents expire in India, pharmaceutical and MedTech companies face a significant opportunity to scale affordable therapies for millions of patients. However, success depends on more than manufacturing capacity.
Additionally, India represents one of the world's largest growth opportunities for GLP-1 therapies, driven by rising prevalence of diabetes and obesity, increasing patient awareness and upcoming generic market expansion.
Yet challenges remain—maintaining product integrity across complex networks, managing the cold chain for biologics, improving patient usability for self-administered therapies, navigating evolving regulations and building resilient packaging ecosystems for growth.
Our latest whitepaper explores how packaging engineering, device integration, cold-chain logistics and regulatory readiness form the foundation for safe, scalable and sustainable GLP-1 adoption across India's diverse healthcare ecosystem.
Key highlights:
- Understanding India's GLP-1 opportunity
Explore the market dynamics shaping the next wave of GLP-1 adoption and the factors influencing long-term commercial success. - Designing robust packaging systems
Learn how primary and secondary packaging choices influence product stability, transport reliability and patient outcomes. - Managing cold-chain complexity
Gain insights into engineering trade-offs, thermal packaging strategies and temperature-control considerations for India's unique distribution landscape. - Improving patient experience
Understand the role of human-centric packaging, usability engineering and integrated delivery systems in supporting therapy adherence. - Scaling with compliance and traceability
Discover key regulatory frameworks, container closure integrity requirements and digital traceability approaches that support large-scale deployment. - Leveraging HCLTech expertise
See how HCLTech supports pharmaceutical and MedTech organizations across packaging engineering, validation, cold-chain qualification, regulatory strategy and digital traceability.
Download the whitepaper to learn how packaging engineering, device integration and supply-chain resilience can help pharmaceutical and MedTech organizations scale GLP-1 therapies safely, efficiently and sustainably in India.
Get your copy now and explore the engineering foundations of next-generation GLP-1 delivery.
